This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Granisetron Nasal Spray

Almac Group

Drug Names(s): ALM101

Description: Granisetron Nasal Spray uses Archimedes' proprietary ChiSys delivery technology. Granisetron is a serotonin 5-HT3 antagonist.

Serotonin 5-HT3 receptors are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of a structure in the brain that controls vomiting and also has an impact on certain autonomic functions (the area postrema). During chemotherapy-induced vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge (ie impulses from the periphery toward the central nervous system) and may induce vomiting. By binding to 5-HT3 receptors and blocking serotonin stimulation, granisetron reduces vomiting.

Deal Structure: In June 2009, Almac Discovery announced a global licensing and development agreement with Archimedes Development to develop a novel intranasal granisetron product. Under the terms of the agreement, Archimedes will be responsible for developing the formulation through to the end of Phase I and will cooperate with Almac Discovery and Galen (a related company of the Almac Group focused on sales and marketing) on clinical development of the product and will receive a series of milestones and royalties as the product progresses through development to launch.

Kyowa Kirin and Archimedes
In July 2014 Kyowa Hakko Kirin subsidiary, Prostrakan Group agreed to acquireArchimedes Pharma Limited from investment companyNovo A/S. The acquisition is expected to close in Q3 2014.

In August 2014, ProStrakan Group announced that it has completed the acquisition of Archimedes Pharma from Novo A/S, following receipt of anti-trust approvals in Germany upon which completion of the...See full deal structure in Biomedtracker

Partners: Kyowa Hakko Kirin Co., Ltd.


Granisetron Nasal Spray News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug